Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb extension study of intravenous vedolizumab for long-term safety in pediatric ulcerative colitis and Crohn's disease
CTR20230051Phase 3Active
- Sponsor
- Takeda
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of vedolizumab in autoimmune colitis, Crohn's disease, sponsored by Takeda. Started Jun 2023; status: active.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on CTR20230051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230051.